Prognostic Significance of CMD Assessed by IMR in HCM Patients
NCT ID: NCT06190704
Last Updated: 2024-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
191 participants
OBSERVATIONAL
2014-09-13
2023-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognostic Value of Angio-IMR in Hypertrophic Cardiomyopathy Patients
NCT06434415
Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy
NCT02994615
Diagnostic and Prognostic Value of Angiography-derived IMR
NCT04825028
Association Between Microvascular Resistance and Outcomes in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT05671367
A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD
NCT07093528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The essential clinical data, including age, gender, systolic and diastolic blood pressure, heart rate, as well as the past medical history encompassing diabetes, hypertension, hyperlipidemia, stroke, atrial fibrillation, heart failure, family history of HCM, syncope, and smoking history, were systematically recorded. Additionally, laboratory parameters such as total cholesterol, high- and low-density lipoprotein, triglycerides, and N-terminal pro-brain natriuretic peptide were documented. The cardiovascular medical medications, including beta-blockers, antiplatelet agents, ACE inhibitors/ARBs, calcium channel blockers, anticoagulants, diuretics, and amiodarone, for all participants were also noted. Data from electrocardiography, echocardiography, and coronary angiography were diligently collected.
Echocardiography was conducted using an available digital ultrasound system by two cardiologists who were unaware of the clinical data. Measurements, including M mode, standard two-dimensional (2D), and pulsed Doppler, were carried out by the guidelines set by the American Society of Echocardiography. Cardiac dimensions were determined using the average of three cardiac cycles. Parameters such as LV ejection fraction, septal and left posterior wall thickness, left atrium diameter, LV end-systolic diameter, LV end-diastolic diameter, and LV outflow tract gradient were assessed.
Coronary angiography was performed at the operators' discretion, capturing multiple views at either 15 or 30 frames per second. caIMR was determined using the Flash Angio system, consisting of the Flash Angio console, Flash Angio software, and Flash Pressure transducer from Rainmed Ltd., Suzhou, China. A validated protocol utilizing computational pressure-flow dynamics (CPFD) was applied for caIMR estimation in three sequential steps. Initially, a simulated three-dimensional reconstruction of coronary arteries was generated for the targeted vessels. Subsequently, angio-Fractional Flow Reserve (angio-FFR) was estimated using CPFD, incorporating the estimated hyperemic aortic pressure (P'a) based on mean aortic pressure. The calculation of caIMR was then performed using the provided equation:
In this context, (Pd)hyp represents the mean pressure at the distal position during maximal hyperemia, with L denoting a constant representing the length from the inlet to the distal position. The constant K is assigned a value of 2.1, and Vdiastole stands for the mean flow velocity at the distal position during diastole. Additionally, Vhyp is calculated as K multiplied by Vdiastole, signifying the mean flow velocity at the distal position during maximal hyperemia.
caIMR was assessed in at least one of the three coronary arteries for all patients in our study. The epicardial vessel exhibiting the highest caIMR value among the three major coronary vessels was chosen for analysis. In the present study, CMD was identified based on caIMR\>25U, consistent with observations from prior research Follow-up was conducted over a mean 43-month period through telephone contact or outpatient visits. The primary clinical endpoints in this study encompassed major adverse cardiac events (MACE), which included: 1) cardiac death: defined as events occurring in the context of cardiac decompensation, pulmonary edema, or progression to end-stage disease, along with other cardiac-related deaths; 2) non-cardiac death: defined as any death occurring during the follow-up period, irrespective of the cause; 3) cardiac readmissions: encompassing hospitalizations for heart failure, myocardial infarction, unstable angina, and malignant arrhythmias; and 4) ischemic stroke: denoting a stroke caused by a blockage in the blood flow to the brain.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CMD
Microvascular function was assessed using caIMR, and 460 coronary arteries were analyzed. CMD was identified with caIMR\>25U, in line with prior research.
caIMR
Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
non-CMD
Microvascular function was assessed using caIMR, and 460 coronary arteries were analyzed. CMD was identified with caIMR≤25U, in line with prior research.
caIMR
Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
caIMR
Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* echocardiographic evidence of HCM, defined as LV myocardial wall thickness of ≥15 mm and or a LV myocardial wall thickness of ≥13 mm in individuals with a family history of HCM, in the absence of an alternative cause for LV hypertrophy
Exclusion Criteria
* second and third-degree atrioventricular block;
* presence of significant epicardial coronary stenosis (≥50% stenosis) on CAG;
* poor life expectancy resulting from concurrent health disease.;
* reduced contrast opacification (for caIMR assessment)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ya-Wei Xu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ya-Wei Xu
Chief Physician
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
caIMR-HCM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.